Search research articles
Contact Us
Filters
Showing results (421-430 of 450) with videos related to
Page
of 45
Sort By:
Gynecologic Oncology
|
May 27, 2026
Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma
Cassidy S Abdeen, Reed M O'Connor, Julia Chalif, et al.
Gynecologic Oncology
|
July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival
Casey M Cosgrove, David E Cohn, Heather Hampel, et al.
Gynecologic Oncology
|
June 14, 2023
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)
B Pothuri, S V Blank, T K Myers, et al.
Gynecologic Oncology
|
July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Nature Communications
|
September 22, 2019
Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery
S Rahima Benhabbour, Martina Kovarova, Clinton Jones, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Gynecologic Oncology
|
October 16, 2022
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study
John K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 1, 2024
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 29, 2025
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
Page
of 45
Search research articles
Search
Showing results (421-430 of 450) with videos related to
Sort By:
Page
of 45
Gynecologic Oncology
|
May 27, 2026
Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma
Cassidy S Abdeen, Reed M O'Connor, Julia Chalif, et al.
Gynecologic Oncology
|
July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival
Casey M Cosgrove, David E Cohn, Heather Hampel, et al.
Gynecologic Oncology
|
June 14, 2023
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)
B Pothuri, S V Blank, T K Myers, et al.
Gynecologic Oncology
|
July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Nature Communications
|
September 22, 2019
Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery
S Rahima Benhabbour, Martina Kovarova, Clinton Jones, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Gynecologic Oncology
|
October 16, 2022
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study
John K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 1, 2024
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 29, 2025
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
Page
of 45